Pharmacology and Analytical Facility - HPLC and Mass Spectrometry Facility This facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and mass spectrometry instruments. In this facility, analytical assay methodologies can be developed and validated using UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiode array, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instruments include a simple single quad LC/MS instrument for use in molecular weight determinations as well as more complex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drug metabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MS instrument is available for separation and quantitation of volatile compounds. Recently added were automated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest (drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organ tissues, and tumors). These extraction systems have improved both extraction efficiency and throughput in analytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug library screening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification, drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility and stability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysis increased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52 faculty members who are members of 21 CCSG Programs;90% of the users have peer-reviewed funding. The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located at a newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a 7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLC systems. In addition to the advanced analytical facility the combined program faculty have in excess of 60 years of experience in analytical chemistry, analytical method development and validation, isolation technologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as an invaluable resource in experimental design, development and implementation to the user faculty who often lack the specific training to conduct experiments requiring quantitative analytical chemistry and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144405
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$466,451
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Jialu; Fu, Chunxiao; Speed, Terence P et al. (2018) Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol 2018:
Fujii, Takeo; Colen, Rivka R; Bilen, Mehmet Asim et al. (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36:638-646
Hoover, Diana Stewart; Wetter, David W; Vidrine, Damon J et al. (2018) Enhancing Smoking Risk Communications: The Influence of Health Literacy and Message Content. Ann Behav Med 52:204-215
Franco, Hector L; Nagari, Anusha; Malladi, Venkat S et al. (2018) Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 28:159-170
Altok, Muammer; Achim, Mary F; Matin, Surena F et al. (2018) A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36:13.e19-13.e25
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2018) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg 22:467-476
Assi, Rita; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol 25:136-145
Viswanath, Pavitra; Peng, Shaohua; Singh, Ratnakar et al. (2018) A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia 20:975-984
Ma, Grace X; Lee, Minsun M; Tan, Yin et al. (2018) Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans. Cancer 124:973-982
Peng, Guang; Mills, Gordon B (2018) Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. Clin Cancer Res 24:508-510

Showing the most recent 10 out of 12418 publications